Table 2. Coagulation abnormalities in CVT patients (N = 43).
| Characteristics | Abnormal group | Normal group | Reference interval* | ||
|---|---|---|---|---|---|
| n (%) | m ± SD | n (%) | m ± SD | ||
| SLP | |||||
| TG (mmol/L) | 8 (18.60%) | 4.78 ± 1.54 | 35 (81.40%) | 1.17 ± 0.42 | 0.50–1.70 |
| CHO (mmol/L) | 28 (65.12%) | 6.72 ± 3.43 | 15 (34.88%) | 4.24 ± 0.45 | 3.20–5.17 |
| HDL (mmol/L) | 3 (6.98%) | 2.86 ± 0.65 | 40 (93.02%) | 1.40 ± 0.24 | 1.00–1.80 |
| LDL (mmol/L) | 24 (55.81%) | 4.64 ± 1.06 | 19 (44.19%) | 2.14 ± 0.32 | 1.50–3.10 |
| APO-A1 (mmol/L) | 15 (34.88%) | 3.58 ± 1.32 | 28 (65.12%) | 1.40 ± 0.16 | 1.20–1.80 |
| APO-B (mmol/L) | 22 (51.16%) | 5.46 ± 2.09 | 21 (48.84%) | 0.86 ± 0.12 | 0.60–1.14 |
| FBG (g/L) | 25 (58.14%) | 4.64 ± 0.32 | 18 (41.86%) | 2.96 ± 0.84 | 2.00–4.00 |
| HCY (μmol/L) | 9 (20.93%) | 43.56 ± 7.85 | 34 (79.07%) | 12.57 ± 2.15 | ≤ 15 |
| PLT (*109/L) | 13 (30.23%) | 365.65 ± 30.64 | 30 (69.77%) | 169.78 ± 15.79 | 100–300 |
| ACL | 2 (4.65%) | — | 41 (95.35%) | — | negative |
| CRP (mg/L) | 5 (11.63%) | 48.95 ± 14.56 | 38 (88.37%) | 1.23 ± 0.45 | 0.00–2.87 |
Note: Abbreviations: SLP, serum lipoprotein; TG, triglyceride; CHO, cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; APO-A1, apolipoprotein A1; APO-B, apolipoprotein B; FBG, fibrinogen; HCY, homocysteine; PLT, platelets; ACL, anticardiolipin antibody; CRP, C-reactive protein. *The normal range of coagulation abnormalities at Beijing Tiantan Hospital.